Tempest Therapeutics (NASDAQ:TPST) Trading Down 1.6% – Time to Sell?

Tempest Therapeutics, Inc. (NASDAQ:TPST) fell 1.6% during trading on Wednesday . The company traded as low as $3.11 and last traded at $3.15. 75,696 shares traded hands during mid-day trading, a decline of 69% from the average session volume of 244,890 shares. The stock had previously closed at $3.20.

Analyst Upgrades and Downgrades

TPST has been the subject of several analyst reports. Wall Street Zen upgraded Tempest Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, October 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tempest Therapeutics in a research note on Thursday, December 4th. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce” and an average target price of $12.50.

Tempest Therapeutics Stock Down 1.6%

The company has a market cap of $13.99 million, a PE ratio of -0.31 and a beta of -2.43. The company’s fifty day moving average is $8.08 and its 200-day moving average is $8.18.

Tempest Therapeutics (NASDAQ:TPST) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($3.27) by $2.48. Equities research analysts expect that Tempest Therapeutics, Inc. will post -1.39 EPS for the current fiscal year.

Institutional Investors Weigh In On Tempest Therapeutics

An institutional investor recently raised its position in Tempest Therapeutics stock. Vanguard Group Inc. lifted its holdings in Tempest Therapeutics, Inc. (NASDAQ:TPST) by 20.8% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 162,560 shares of the company’s stock after purchasing an additional 27,952 shares during the period. Vanguard Group Inc. owned about 3.66% of Tempest Therapeutics worth $1,671,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 22.52% of the company’s stock.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.